Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dutasteride with CAB in Salivary Duct Carcinoma
NCT05513365Phase 2Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2022
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dutasteride in salivary duct carcinoma (SDC) (2 arms), sponsored by Radboud University Medical Center. Primary endpoints: Overall Response Rate at 2 years and Duration of Response at 2 years. Started Sep 2022; status: recruiting.
02
Drugs
dutasteride
03
Conditions
salivary duct carcinoma (SDC)
Beyond the preview
Go deeper on NCT05513365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05513365.